Home » Stocks » Merrimack Pharmaceuticals

Merrimack Pharmaceuticals, Inc. (MACK)

Stock Price: $3.61 USD 0.00 (0.00%)
Updated Aug 13, 2020 4:00 PM EDT - Market open
After-hours: $3.66 +0.05 (1.39%) Aug 13, 4:22 PM

Stock Price Chart

Key Info

Market Cap 48.30M
Revenue (ttm) n/a
Net Income (ttm) 1.64M
Shares Out 13.38M
EPS (ttm) 0.12
PE Ratio 30.08
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 13, 2020
Last Price $3.61
Previous Close $3.61
Change ($) 0.00
Change (%) 0.00%
Day's Open -
Day's Range 3.24 - 3.63
Day's Volume 0
52-Week Range 1.49 - 7.09

More Stats

Market Cap 48.30M
Enterprise Value 32.57M
Earnings Date (est) Nov 4, 2020
Ex-Dividend Date n/a
Shares Outstanding 13.38M
Float 8.23M
EPS (basic) 0.12
EPS (diluted) 0.12
FCF / Share -0.66
Dividend n/a
Dividend Yield n/a
Earnings Yield 3.32%
FCF Yield n/a
Payout Ratio n/a
Shares Short 489,232
Short Ratio 23.10
Short % of Float 4.87%
Beta 2.39
PE Ratio 30.08
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 2.71
Revenue n/a
Operating Income -4.04M
Net Income 1.64M
Free Cash Flow -8.83M
Net Cash 15.74M
Net Cash / Share 1.18
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -18.88%
ROE -7.99%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

$4.00*
Low
4.00
Current: $3.61
High
4.00
Target: 4.00
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue-----10347.7948.9234.2220.31
Revenue Growth-----115.03%-2.32%42.98%68.51%-
Gross Profit-----10347.7948.9234.2220.31
Operating Income-22.36-65.58-95.77-147-145-66.26-121-92.74-80.87-49.18
Net Income-17.33-40.51472-152-148-83.29-131-91.28-79.22-50.10
Shares Outstanding13.3513.3413.2312.5311.1410.449.897.281.131.10
Earnings Per Share-1.30-3.0335.67-12.11-13.29-8.00-13.20-12.80-76.70-55.70
Dividend Per Share2.00-10.55-------
Operating Cash Flow-31.37-65.59-126-170-105-34.81-95.18-79.82-52.82-26.37
Capital Expenditures2.03-0.040.18-2.64-11.90-6.04-9.86-3.19-3.75-5.00
Free Cash Flow-29.34-65.63-126-173-117-40.84-105-83.01-56.57-31.37
Cash & Equivalents16.5871.8694.2222.3018612515611150.8431.09
Total Debt-14.87-21725812011239.860.050.49
Net Cash / Debt16.5856.9994.22-195-71.364.7144.2170.7350.7930.60
Assets20.0888.5411781.4823515919214985.3057.58
Liabilities2.7729.7221.0433441926123615510785.26
Book Value17.3158.8296.28-250-184-102-43.80-6.61-291-221
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Merrimack Pharmaceuticals, Inc.
Country United States
CEO Gary L. Crocker

Stock Information

Ticker Symbol MACK
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: MACK
IPO Date March 29, 2012

Description

Merrimack Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that targets biomarker-defined cancers. The company is developing MM-310, an antibody-directed nanotherapeutic, which is in Phase I clinical trial to treat patients with solid tumors. Its preclinical product candidates include MM-401, an agonistic antibody targeting a novel immuno-oncology target; and MM-201, a stabilized agonist-Fc fusion protein targeting death receptors 4 and 5. The company has a collaboration and license agreement with Ipsen S.A. Merrimack Pharmaceuticals, Inc. was incorporated in 1993 and is based in Cambridge, Massachusetts.